Tag: drug pricing
-
Trump Administration Reaches Deals to Lower GLP-1 Weight Loss Drug Prices for Medicare Patients
The Trump administration announced a set of price-lowering agreements on Thursday with two of the world’s leading pharmaceutical companies, Novo Nordisk and Eli Lilly. The deals target GLP-1 receptor agonists—drugs widely prescribed for weight management and diabetes—that have faced scrutiny for their rising costs in recent years. By negotiating rebates and price caps, officials say…
-
Trump Admin Secures Deals to Lower GLP-1 Weight-Loss Drug Prices for Medicare and Private Patients
Overview: Aiming to curb rising costs for GLP-1 medications The Trump administration announced a landmark set of deals on Thursday with the pharmaceutical giants Novo Nordisk and Eli Lilly. The agreements are designed to reduce the out-of-pocket and list prices of GLP-1 drugs—medications increasingly prescribed for weight management and diabetes—especially for Medicare beneficiaries and other…
-
Third of New Cancer Drugs Improve Survival Rates: Ireland’s Pharmacoeconomics Debate
Overview: A Third of New Cancer Drugs Improve Survival Recent discussions at a conference on medicines in Ireland highlighted a striking paradox: while new cancer drugs hold promise, only about a third demonstrably extend overall survival for patients. The head of the National Centre for Pharmacoeconomics warned that many cancer therapies—even those approved—do not translate…
-
New Cancer Drugs: Survival Rates and Value in Ireland
Overview: Balancing Innovation with Value for Money The latest insights from Ireland’s National Centre for Pharmacoeconomics (NCPE) highlight a key tension in modern oncology: while many new cancer medicines promise breakthroughs, only a fraction clearly improves overall survival for patients. At a recent medicines conference, Professor Michael Barry outlined that roughly one third of newly…
-
Third of New Cancer Drugs Improve Survival Rates
Summary: A balance between benefit and cost Recent insights from Ireland’s National Centre for Pharmacoeconomics highlight a cautious reality in cancer care. While many new medicines promise advances in treatment, only about one in three new cancer drugs demonstrate an improvement in overall survival. This finding comes as the centre assesses value for money to…
-
Trump Imposes 100% Tariffs on Medicines: AstraZeneca Hit
Executive overview: 100% tariffs on medicines In a move that has stoked alarms across the pharmaceutical sector, the United States plans to impose 100 percent tariffs on imported medicines starting October 1. The sweeping policy targets a wide range of drugs and could push up costs for patients and disrupt established supply chains, even as…
-
Trump tariffs: Who stands to lose from new US pharma duties?
Trump’s latest tariff move arrives as a social-media surprise, with a 100% duty on branded or patented pharmaceutical products entering the United States unless manufacturers are building or planning to build US facilities. The post, made on Truth Social, did not include formal legislation, leaving industry and investors to parse what such a policy would…